BICO has agreed to sell Nanoscribe to LAB14 GmbH for an equity value of EUR26m (SEK294m), with the transaction set to close in Q4 2024. We are pleased to see the company executing the BICO 2.0 strategy shared during CMD 2024, which designates Nanoscribe as non-core due to its primary focus outside
Yesterday, BICO held a Capital Markets Day (CMD) where the new top executive management team provided an in-depth view of the renewed BICO 2.0 strategy. Aware of the Life Science (LS) Tools and Bioconvergence post-pandemic tough market conditions, the company's new vision focuses on Lab Automation
BICO has reported Q2 2024 results indicating a certain positive trend on profitability development with all segments reporting EBITDA positive for the first time despite sales remaining flatish. Net sales amounted to SEK 534m implying 5% QoQ growth yet a decrease of 1.3% YoY. The Biosciences segmen
BICO has reported Q1 2024 net sales amounting to SEK 510.3m (+2% vs. css) implying 4.4% YoY growth and organic growth of 4.7% (-1.1%). The Biosciences segment outperformed with net sales showing 36.3% organic growth to SEK 310m (SEK 230m), while Bioprinting and Bioautomation fell short of expectati
Given team and strategy changes, Oscar Haffen Lamm is now assuming coverage of Medincell, Camurus, Valneva, Aelis Pharma, Abivax, Calliditas, Egetis Therapeutics, Basilea, Geneuro, Achilles, Valerio, Innate Pharma, Morphosys, Inventiva Pharma, Vicore, DBV Technologies, and Genfit.Maria Vara is now
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.